GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs.

Kymera Therapeutics has developed KT-579, a potent and selective IRF5 degrader as a novel approach for treating systemic lupus erythematosus (SLE) and Sjögren disease.

At the recent American Diabetes Association meeting, researchers from Century Therapeutics Inc. presented preclinical efficacy data on CNTY-813, an induced pluripotent stem cell (iPSC)-derived cell therapy engineered using the company’s proprietary Allo-Evasion 5.0 platform.

Tango Therapeutics Inc. will be sitting down with the U.S. FDA soon to discuss pivotal work ahead based on what Cantor analyst Eric Schmidt called “amazing” data from the phase I/II study of vopimetostat, a PRMT5 inhibitor, paired with Revolution Medicines Inc.’s RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) as well as non-small cell lung cancer.

Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis.

Researchers at Obleno Bio Inc. have reported preclinical efficacy data for LBL-051-S3, a trispecific T-cell engager antibody targeting CD3, CD19 and BCMA, in nonhuman primate models.

At the recent European Congress of Rheumatology (EULAR) meeting in London, researchers from Antegene Corp. Ltd. presented the preclinical characterization of ATG-207, an αCD3-TGF-β bifunctional fusion protein, in models of T-cell-driven autoimmune disease.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) play crucial roles in B-cell differentiation and survival. Genescience Pharmaceutical Co. Ltd. has released data for its dual BAFF and APRIL inhibitor Gensci-136 for the treatment of SLE.

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base.

About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure.